NPPB and hydrops fetalis: Supporting the presence of sex differences in DbCM, the recent phase 3 ARISE-HF trial, which evaluated the effects of AT-001 in patients with DbCM, highlighted sex-specific baseline characteristics—such as higher NT-proBNP levels, more preserved LV function, and greater symptomatic burden in women compared to men [65].